United Therapeutics Director Christopher Patusky Receives Stock Options and Common Stock Award

Annual Non-Employee Director Equity Grant Structure

Christopher Patusky, serving as a director at United Therapeutics, received an annual non-employee director award consisting of both stock options and common stock. The option grant comprised 2,380 options with an exercise price of $527.07 per share, while the common stock component included 2,410 shares acquired at no stated consideration price. This dual-component approach reflects a standard director compensation model used by many biopharmaceutical firms to align board member interests with shareholder value.

The timing of this award on July 22, 2026, represents the company's regular annual director compensation cycle. United Therapeutics structures non-employee director equity awards to encourage long-term board member retention and incentivize performance aligned with shareholder interests. The magnitude of the awards and their vesting conditions are designed within frameworks established by the company's board compensation committee.

Vesting Schedule and Exercise Parameters for Director Options

The 2,380 stock options granted to Patusky carry a seven-year expiration date, with full expiration occurring on July 22, 2033. These options become fully vested on the earlier of two triggering events: either the one-year anniversary of the grant date, or the date of the next Annual Meeting of Shareholders. United Therapeutics anticipates this shareholder meeting to occur on June 25, 2027, which would constitute the earlier vesting trigger under the plan's terms.

The $527.07 exercise price represents the market valuation basis used for option calculation at the time of grant. This pricing methodology ensures that director compensation reflects fair value principles at the moment of award issuance. The vesting structure provides a clear timeline for Patusky's ability to exercise the options, aligning incentive realization with either time-based service or significant corporate governance events.

United Therapeutics Board Governance and Director Role

United Therapeutics Corporation operates as a biopharmaceutical company focused on developing innovative therapies across multiple therapeutic areas. The company's board of directors includes both employee and non-employee members, with Christopher Patusky holding a non-employee director position. Non-employee directors at public companies typically participate in board committees, contribute independent oversight, and provide strategic guidance while maintaining independence from day-to-day operational management.

The equity compensation provided to non-employee directors serves multiple strategic purposes within corporate governance frameworks. By granting stock options and common shares, United Therapeutics creates financial incentives for directors to monitor management performance, evaluate strategic initiatives, and act in the best interests of long-term shareholder value creation. This approach is consistent with practices across the biopharmaceutical sector, where director compensation often combines cash retainers with equity-based components.

Direct Ownership Following Equity Award Transaction

Following the transaction dated July 22, 2026, Patusky maintained direct beneficial ownership of the newly acquired securities. The 2,410 common shares are held in direct form, meaning Patusky has immediate legal title and voting rights over these securities without any intermediary arrangement. Additionally, the 2,380 options granted are beneficially owned directly, with Patusky possessing the right to exercise these derivative securities upon satisfaction of vesting conditions.

The direct ownership structure provides Patusky with clear control over decision-making regarding these securities, including voting rights on common shares and exercise decisions once options become vested. This transparent ownership arrangement aligns with regulatory requirements for beneficial ownership disclosure and reflects straightforward compensation delivery without complex structuring mechanisms.

Regulatory Disclosure and Section 16 Reporting Requirements

This transaction disclosure was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which governs beneficial ownership reporting by directors, officers, and principal shareholders of public companies. Christopher Patusky, as a director of United Therapeutics, qualifies as a Section 16 reporting person subject to these disclosure obligations. The company confirmed that Patusky remains subject to Section 16 reporting requirements, indicating his continued director status at the time of filing.

The disclosure indicates that this transaction was not made pursuant to a Rule 10b5-1 trading plan, meaning the equity award was not part of a pre-arranged systematic trading arrangement designed to avoid insider trading concerns. Instead, the grant represents a discrete equity compensation event managed through the company's director compensation program, with routine authorization and approval following established board governance protocols.

Biopharmaceutical Sector Context and Director Compensation Trends

United Therapeutics operates within the biopharmaceutical industry, where equity-based director compensation has become standard practice among publicly traded companies. The sector is characterized by significant research and development expenditures, regulatory compliance complexities, and long product development timelines requiring experienced board oversight. Directors at biopharmaceutical firms typically bring scientific, clinical, regulatory, or business expertise essential for evaluating strategic initiatives and management performance in this specialized domain.

Director equity awards in the biopharmaceutical sector typically represent a meaningful component of total compensation, reflecting the importance boards place on securing experienced independent directors willing to commit substantial time and intellectual capital. The option exercise price of $527.07 per share referenced in Patusky's award provides insight into United Therapeutics' share valuation at the award date, though the filing itself does not provide commentary on market conditions or valuation multiples at that time.

Corporate Governance Framework and Board Compensation Philosophy

United Therapeutics implements a formalized board compensation structure that distinguishes between employee and non-employee director awards. The timing of Patusky's annual grant reflects the company's established practice of delivering director equity compensation on a regular schedule, likely coordinated with annual governance cycles and board meeting calendars. Non-employee director compensation plans typically include cash retainers, meeting fees, and annual equity awards calibrated to market practices among comparable public companies.

The structure of director compensation—combining fixed cash components with variable equity awards—creates a balanced incentive framework encouraging directors to focus on both near-term operational oversight and long-term value creation. The use of stock options with multi-year vesting periods further reinforces this long-term alignment philosophy, as directors benefit from sustained stock price appreciation only if they continue holding positions and if the company delivers shareholder value over extended periods.

Execution and Authentication of Beneficial Ownership Update

The beneficial ownership disclosure was executed by John S. Hess, Jr., acting under power of attorney on behalf of Christopher Patusky, with the document signed and filed on July 23, 2026. This delegation of signing authority to a legal representative is a common administrative practice in securities law compliance, allowing directors to maintain current disclosures without personally executing each regulatory filing. The power of attorney mechanism provides proper authorization for the representative to attest to the accuracy and completeness of the reported transaction information.

The filing represents a formal statement regarding changes in beneficial ownership, with regulatory significance for investors monitoring insider trading activity and director holdings at United Therapeutics. The document's completion includes all required elements for compliance with Securities and Exchange Commission regulations, ensuring proper notice to the market regarding changes in director equity stakes and compensation arrangements.